Compare prices and buy MGF (Mechano Growth Factor) from 3 research peptide vendors - also called suppliers or sources. Updated daily.
A synthetic peptide corresponding to the C-terminal E-domain of IGF-1Ec, the alternative splice variant of insulin-like growth factor-1 known as mechano growth factor. Its expression rises in skeletal muscle after mechanical loading or damage, and in cell studies the E-domain peptide increased myoblast proliferation by a route that IGF-1 receptor blockade did not stop. Studied in cell culture and in animal models of muscle repair and myocardial infarction. No registered human trials and not FDA-approved.
For research purposes only. Not medical advice.
Mechano growth factor, or MGF, takes its name from a splice variant of the IGF-1 gene. In human nomenclature the variant is IGF-1Ec, while some papers, including a 2010 minireview in Endocrinology (Matheny, Nindl and Adamo), call it IGF-1Eb. A 2012 review in Frontiers in Endocrinology (Zablocka and colleagues) traces that confusion to splicing that yields slightly different reading frames in rodents and humans. The variant shares its mature IGF-1 region with the other IGF-1 forms and differs in its E domain.
What vendors sell is not the whole isoform. It is a synthetic peptide matching the last 24 residues of that E domain, which FDA's Global Substance Registration System registers as mechano growth factor, sequence YQPPSTNKNTKSQRRKGSTFEERK, under UNII Q86M4KXC2P. Because the peptide lies outside the 70-residue mature hormone, it contains none of mature IGF-1's sequence. The 2010 minireview added that no matching peptide product of the IGF-1 gene had been identified in or isolated from cultured cells, animal tissues or body fluids.
PEG-MGF is the same peptide with polyethylene glycol attached, and PeptideScouter indexes it as a separate row.
The name comes from work on the body's own transcript, not on the synthetic peptide. In rats, Hill and Goldspink (Journal of Physiology, 2003) found MGF mRNA in the tibialis anterior rose rapidly after mechanical damage or a bupivacaine injection and declined within a few days, while the IGF-1Ea transcript rose more slowly. In people, Hameed and colleagues (Journal of Physiology, 2003) took quadriceps biopsies 2.5 hours after a single bout of high-resistance exercise and found MGF mRNA increased in young subjects but not in those aged 70 to 82. At rest it ran about 100-fold below IGF-1Ea.
These studies measure gene expression. They do not show what the synthetic peptide does when it is given.
The studies usually cited for the synthetic peptide are cell and animal work:
The cell result has not held up everywhere. Fornaro and colleagues (American Journal of Physiology - Endocrinology and Metabolism, 2014), working at two pharmaceutical companies, found the peptide did not increase proliferation of mouse C2C12 cells or primary human myoblasts, did not inhibit their differentiation and had no significant effect on primary mouse muscle stem cells, while mature IGF-1 did stimulate proliferation. They wrote that the results call into question whether MGF has a physiological role.
A 2026 narrative review in Frontiers in Endocrinology (Dominikowski and colleagues) describes the MGF evidence base as predominantly preclinical, with unresolved questions about mechanism, translatability and safety. A ClinicalTrials.gov search on October 22, 2026 for mechano growth factor as an intervention returned no study that gives MGF or its E-domain peptide to people. The one registered study naming IGF-1Ec is observational and measures its serum level in patients with solid tumors.
MGF is not an FDA-approved drug, and drugsfda returns no match for mechano growth factor as of October 22, 2026. FDA's list of bulk drug substances nominated for compounding under Section 503A places "Mechano growth factor (MGF)" in Category 3, which the document heads Bulk Drug Substances Nominated Without Adequate Support, in both its September 27, 2024 and May 14, 2026 versions. It appears neither in FDA's 503B nominations list (updated March 21, 2025) nor on FDA's Category 2 safety-risk page, which names only the pegylated form. The PEG-MGF page covers that form's separate compounding record.
In sport, the World Anti-Doping Agency's 2027 Prohibited List names mechano growth factors in section S2.3, part of a class prohibited at all times, in and out of competition.
Vendor titles read "MGF (Mechano Growth Factor)" or "MGF without PEG", the second spelling out that the vial is not the pegylated product. One listing's specification block gives a sequence length of 24 amino acids, matching the GSRS record, and another describes MGF as the IGF-1Ec splice variant. Every MGF listing indexed here is sold as vials, so each carries a per-milligram price.
No. MGF is named for IGF-1Ec, a splice variant of the IGF-1 gene that shares the mature IGF-1 region with other IGF-1 forms and differs in its E domain. The peptide sold as MGF is a synthetic match to the last 24 residues of that E domain, registered in FDA's Global Substance Registration System under UNII Q86M4KXC2P, and it contains none of the 70-residue mature IGF-1 sequence. A 2002 cell study reported that blocking the IGF-1 receptor pointed to a different receptor for its effect on myoblasts, while a 2014 study by researchers at two pharmaceutical companies found no effect on myoblast proliferation or differentiation.
Not as an administered peptide. The human data concern the body's own MGF transcript: a 2003 Journal of Physiology study found MGF mRNA in thigh muscle rose after a single bout of high-resistance exercise in young subjects but not in subjects aged 70 to 82. The studies usually cited for the synthetic peptide are cell culture and animal work, and a ClinicalTrials.gov search on October 22, 2026 found no registered study that gives MGF or its E-domain peptide to people.
MGF is not an FDA-approved drug. FDA's list of bulk drug substances nominated for compounding under Section 503A places mechano growth factor (MGF) in Category 3, bulk drug substances nominated without adequate support, in both its September 2024 and May 2026 versions, and it does not appear on FDA's 503B nominations list. The pegylated form, PEG-MGF, is a separate nomination with its own record.
Yes. The World Anti-Doping Agency's 2027 Prohibited List, which takes effect on January 1, 2027, names mechano growth factors (MGFs) in section S2.3, growth factors and growth factor modulators. Everything in section S2 is prohibited at all times, in and out of competition.
The phrase separates the unmodified MGF peptide from PEG-MGF, the same peptide with polyethylene glycol attached. PeptideScouter indexes the two as separate compounds because they are different substances, and FDA has handled them as separate compounding nominations.
MGF (Mechano Growth Factor) is sold by 3 research peptide vendors indexed on PeptideScouter, with 4 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
MGF (Mechano Growth Factor) is currently out of stock across all 3 tracked vendors. The comparison table shows last-seen pricing for reference, and stock state is refreshed daily.
Alpha Peptides currently lists MGF (Mechano Growth Factor) at $11.63/mg (currently out of stock), the lowest listed price across 3 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $10.47/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 3 vendors listing MGF (Mechano Growth Factor) publish a PeptideScouter code, worth 10% off. Applied, the lowest effective price falls from $11.63/mg listed to $10.47/mg at Alpha Peptides. Each vendor's code is shown beside its price in the table above.
MGF (Mechano Growth Factor) ranges from $11.63/mg to $21.50/mg across 4 listings from 3 research peptide vendors, normalized to USD per milligram and refreshed daily.
3 research peptide vendors currently list MGF (Mechano Growth Factor) on PeptideScouter. We track 4 listings across size and kit variants.
MGF (Mechano Growth Factor)'s CAS Registry Number is 12020-86-9. It is also sold as MGF IGF-1, MGF without PEG.
